Introduction

Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors.

Objective

We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile.

Methods

In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data.

Results

Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11).

Conclusions

KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile.

Clinical Trials Registry

Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.

中文翻译：

---

氯化钾对糖尿病和心血管疾病的代谢组学通路影响的初步证据。

介绍

钾摄入量低会影响心血管疾病（CVD）风险和心脏代谢风险因素。

目的

我们假设补充氯化钾（KCl）可以改善心血管风险代谢组学特征。

方法

在对26名糖尿病前期患者随机分为KCl或安慰剂的试验性随机临床试验（RCT）的二级分析中，我们对基线和12周（研究结束）血浆样品进行了基于质谱的靶向代谢组学分析。主成分分析（PCA）用于将许多相关的代谢物还原为较少的独立因素，从而将大部分信息保留在原始数据中。

结果

服用KCl的人的支链氨基酸（BCAA）因子（P  = 0.004）和缬氨酸水平（P  = 0.02）显着降低（相应地降低了心血管风险）。以及短链酰基肉碱（SCA）因子的无明显降低（P  = 0.11）。

结论

补充KCl可能会改善循环中BCAA的水平，这可能反映出整体心脏代谢风险的改善。

临床试验注册

Clinicaltrials.gov标识符：NCT02236598；https://clinicaltrials.gov/ct2/show/NCT02236598。